Cardiolooncology Department, Personalized Medicine Centre, Almazov National Medical Research Centre, Sankt-Peterburg, Russian Federation.
Personalized Medicine Centre, Almazov National Medical Research Centre, Sankt-Peterburg, Russian Federation.
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241238210. doi: 10.1177/10760296241238210.
Postoperative venous thromboembolism (VTE) is a frequently occurring complication among glioma patients. Several risk assessment models (RAMs), including the Caprini RAM, the IMPROVE Risk Score, the IMPROVED VTE Risk Score, and the Padua Prediction Score, have not been validated within the glioma patient population. The purpose of this study was to assess the predictive accuracy of established VTE risk scales in patients with glioma.
A single-center, retrospective, observational cohort study was conducted on 265 glioma patients who underwent surgery at the Almazov Medical and Research Centre between 2021 and 2022. VTE detection followed the current clinical guidelines. Threshold values for the Caprini, IMPROVE VTE, IMPROVEDD, and Padua scales were determined using ROC analysis methods, with cumulative weighting for sensitivity and specificity in predicting VTE development. The areas under the ROC curves (AUC) were calculated, and comparisons were made using the DeLong test.
The area under the curve for the Caprini risk assessment model was 80.41, while the IMPROVEDD VTE risk score was 75.38, the Padua prediction score was 76.9, and the IMPROVE risk score was 72.58. No significant differences were observed in the AUC values for any of the scales. The positive predictive values of all four scales were low, with values of 50 (28-72) for Caprini, 48 (28-69) for IMPROVEDD VTE, 50 (30-70) for Padua, and 64 (35-87) for IMPROVE RAM. No significant differences were found in terms of PPV, NPV, positive likelihood ratio, and negative likelihood ratio among the analyzed scales.
The Caprini Risk Assessment Model, the IMPROVE Risk Score, the IMPROVED VTE Risk Score, and the Padua Prediction Score exhibit acceptable specificity and sensitivity for glioma patients. However, their low positive predictive ability, coupled with the complexity of interpretation, limits their utility in neurosurgical practice.
术后静脉血栓栓塞症(VTE)是胶质瘤患者常见的并发症。几种风险评估模型(RAMs),包括 Caprini RAM、IMPROVE 风险评分、改良 VTE 风险评分和 Padua 预测评分,尚未在胶质瘤患者人群中得到验证。本研究旨在评估已建立的 VTE 风险量表在胶质瘤患者中的预测准确性。
对 2021 年至 2022 年期间在阿尔马佐夫医疗研究中心接受手术的 265 名胶质瘤患者进行了一项单中心、回顾性、观察性队列研究。VTE 的检测遵循当前的临床指南。使用 ROC 分析方法确定 Caprini、IMPROVE VTE、IMPROVEDD 和 Padua 量表的阈值,对灵敏度和特异性进行累积加权,以预测 VTE 发生。计算 ROC 曲线下面积(AUC),并使用 DeLong 检验进行比较。
Caprini 风险评估模型的 AUC 为 80.41,而改良 VTE 风险评分的 AUC 为 75.38,Padua 预测评分的 AUC 为 76.9,改良风险评分的 AUC 为 72.58。任何一个量表的 AUC 值均无显著差异。四个量表的阳性预测值均较低,Caprini 为 50(28-72),改良 VTE 为 48(28-69),Padua 为 50(30-70),改良风险评分为 64(35-87)。分析的量表之间在阳性预测值、阴性预测值、阳性似然比和阴性似然比方面无显著差异。
Caprini 风险评估模型、改良风险评分、改良 VTE 风险评分和 Padua 预测评分对胶质瘤患者具有可接受的特异性和敏感性。然而,它们的阳性预测能力较低,加上解释的复杂性,限制了它们在神经外科实践中的应用。